Akero Therapeutics
AKRO
AKRO was delisted on the 8th of December, 2025.
0 hedge funds and large institutions have $0 invested in Akero Therapeutics in 2026 Q1 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, reducing their positions, and 2 closing their positions.
0.02% less ownership
Funds ownership: 0.02% → 0% (-0.02%)
100% less funds holding
Funds holding: 2 → 0 (-2)
100% less capital invested
Capital invested by funds: $533K → $0 (-$533K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
|
-$532K |
| 2 |
IA
IFP Advisors
Tampa,
Florida
|
-$984 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
| – | -$532K | -20,000 | Closed |
|
|
IA
2
IFP Advisors
Tampa,
Florida
| – | -$984 | -18 | Closed |
|
AKRO Hedge Fund Activity: Q1 2026 in Review
0 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in Akero Therapeutics (AKRO) for Q1 2026, worth a combined $0 — down 100% from $533K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of AKRO and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was DekaBank Deutsche Girozentrale, exiting entirely with an estimated $532K sold.
- 0 institutional investors held Akero Therapeutics (AKRO) as of Q1 2026, down from 2 in Q4 2025.
- Funds reported $0 of Akero Therapeutics stock for Q1 2026, down 100% quarter-over-quarter.
- 0 funds opened new Akero Therapeutics positions in Q1 2026 and 2 closed out, a net change of -2 holders.
- The largest Akero Therapeutics seller in Q1 2026 was DekaBank Deutsche Girozentrale, an estimated $532K sold.
Based on aggregated 13F filings for Q1 2026.